ClinicalTrials.govpublic full text
Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma
autologous hematopoietic stem cell transplant recipient, loss of chromosome 17p, plasma cell leukemia, recurrent plasma cell myeloma, refractory plasma cell myeloma, interventional, phase1
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 834984
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.